# Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered

> **NCT01068743** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 24 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** saxagliptin
- **DRUG:** metformin
- **DRUG:** saxagliptin + metformin (FDC tablet)

## Key facts

- **NCT ID:** NCT01068743
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01068743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01068743, "Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01068743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*